Tag:
Alnara Pharmaceuticals
Latest Headlines
Latest Headlines
Frazier preps venture fund to back biotechs built for sale
Alan Frazier, the founder of Frazier Healthcare Ventures, tells Xconomy's Luke Timmerman that he's preparing to raise a new fund. And while many venture outfits have been moaning and groaning about
Biotech VCs back startup Allena Pharma in $15M A round
Alexey Margolin and Bob Gallotto are getting their biotech band back together. Allena Pharmaceuticals, their latest startup, has nailed down $15 million in a Series A round of financing led by a trio
Regulators hand Eli Lilly another new drug rejection
Eli Lilly suffered yet another setback at the hands of U.S. regulators late on Friday. The FDA told Lilly that it would need to conduct another study of a new treatment designed to help a group of
Lilly CEO: Pipeline to soften patent losses
Eli Lilly ( NYSE: LLY ) is looking to its pipeline to fill the gaps left by a number of high-profile drugs comping off patent. In October 2011, blockbuster Zyprexa will fall to generic competition;
Lilly buys Alnara for undisclosed sum
Alnara Pharmaceuticals has inked a deal to merge with Eli Lilly for an undisclosed sum. The Cambridge, MA-based developer's lead product is liprotamase, a therapy under FDA review for the treatment
Westphal grabs reins at GSK's SR One, founds new venture group
Christoph Westphal is adding a new chapter to his story as a prime mover-and-shaker in biotech circles. Xconomy reports that Westphal has resigned as CEO of Sirtris, a high-profile developer in
Alnara rises from Altus' ashes
Just 16 months after raising $20 million in its first round of funding, Massachusetts-based Alnara Pharmaceuticals says it's preparing an NDA for its cystic fibrosis treatment. It's a drug that was
Alnara grabs $35M in VC cash as it aims at NDA
Alnara Pharmaceuticals has assembled the financing it needs to push its lead product--liprotamase, an enzyme replacement therapy for cystic fibrosis patients--through an NDA this quarter and on to
Alnara licences liprotamase from CF Foundation
In late January, Altus Pharmaceuticals became yet another biotech company to fall victim to the economic crisis. The Waltham, MA-company announced that it would cut jobs and narrow its research focus
Alnara gets $20M in first round
Boston-based Alnara Pharmaceuticals has garnered $20 million in its first round of venture capital financing. Frazier Healthcare Ventures and Third Rock Ventures led the round, with participation
